Loading viewer...
investor_presentation
Format: PDF investor_presentation
We target clinically underserved cancers March 2022
We target clinically underserved cancers
This presentation contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be
considered forward- looking statements, including statements relating to our development of AL101 and AL102, the promise and potential impact of our preclinical or clinical trial data, the timing of and plans to initiate additional clinical trials
of AL101 and AL102, the timing and results of any clinical trials or readouts, the sufficiency of cash to fund operations, and the anticipated impact of COVID- 19, on our business. These forward- looking statements are based on
management's current expectations. The words ”may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “tar get,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar
expressions are intended to identify forward- looking statements, although not all forward- looking statements contain these identifying words.
These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward- looking statements, including, but not limited to, the following: we have incurred significant losses since inception and anticipate that we will continue to incur
losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability; we wil l require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to
complete the development and commercialization of AL101 and AL102; we have a limited operating history and no history of comm ercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future
viability; we are heavily dependent on the success of AL101 and AL102, our most advanced product candidates, which are still under clinical development, and if either AL101 or AL102 does not receive regulatory approval or is not
successfully commercialized, our business may be harmed; due to our limited resources and access to capital, we must prioriti ze development of certain programs and product candidates; these decisions may prove to be wrong and may
adversely affect our business; the outbreak of COVID- 19, may adversely affect our business, including our clinical trials; our ability to use our net operating loss carry forwards to offset future taxable income may be subject to certain
Preview truncated — download the full document for the complete content.
Ayala Corporation 2023 Investor Presentation
investor_presentationinvestor_presentation
14 Pages
investor_presentation
30 Pages
Inter & Co
Balaxi Pharmaceuticals Investor Presentation - Frontier Markets
investor_presentationinvestor_presentation
21 Pages
Balaxi Pharmaceuticals Limited